Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review
| Author | Mohsen Arabi | en |
| Author | Raheleh Alimoradzadeh | en |
| Author | Alireza Makian | en |
| Author | Seyed Javad Shariat Nabavi | en |
| Author | Farshad Divsalar | en |
| Author | Mitra Kazemi Jahromi | en |
| Orcid | Raheleh Alimoradzadeh [0000-0002-9049-2963] | en |
| Orcid | Mitra Kazemi Jahromi [0000-0002-9127-3594] | en |
| Issued Date | 2022-07-31 | en |
| Abstract | Nonalcoholic fatty liver disease (NAFLD) refers to fat accumulation in hepatic cells due to alcohol consumption, hepatitis, and drugs. The prevalence of this disease has been reported at 20 - 50% in western and 12 - 13% in Latin countries. Patients who suffer from obesity, diabetes, and insulin resistance may be affected more than others. This disease is symptomless, and its paraclinical diagnosis is achievable by increasing the hepatic enzymes. Ultrasonography and fibroscan are some of the common diagnostic methods for this disease. The first treatment for this disease is weight loss and physical activities. Vitamin E can improve histopathological changes in terms of medications. While pioglitazone is an effective blood sugar-lowering drug, metformin has no role in treating diabetes or prediabetes. | en |
| DOI | https://doi.org/10.5812/jhrt-119454 | en |
| Keyword | Nonalcoholic Fatty Liver | en |
| Keyword | NAFLD | en |
| Keyword | Nonalcoholic Steatohepatitis | en |
| Keyword | NASH | en |
| Keyword | Diagnosis | en |
| Keyword | Treatment | en |
| Keyword | Guideline | en |
| Publisher | Brieflands | en |
| Title | Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review | en |
| Type | Review Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- jhrt-8-3-119454.pdf
- Size:
- 235.85 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF